Myocardial Solutions’ (MSI) mission is to give cardiac and oncology patients control over their heart health. By quantifying subtle changes in myocardial heart function, MSI's proprietary MyoStrain® technology provides a standardized, proactive approach to help physicians effectively detect, monitor, and manage the early progression of myocardial dysfunction.
With 70,000+ patient data points from over 70 medical centers in the United States and EU, MyoStrain has been rigorously validated in over 400+ publications, including 50+ in JACC and Circulation. The MyoStrain heart function test is a rapid, non-invasive MRI scan performed in under 10 and has been optimized for clinical use due to its speed, ease of use, and quantitative accuracy.
We are working with hospitals and cancer centers in the United States and Europe to help transform quality of care for their patients. Together, we are pursuing a higher standard of care, focusing preventative care and personalized medicine to ultimately improve patient longevity and quality of life in cardiology and oncology.
John Funkhouser has extensive experience in healthcare as Chief Executive Officer of four cardiac life sciences companies including CoeurLabs, PharmaNetics, nContact and now, MSI. Before working in healthcare, Mr. Funkhouser worked in banking and venture capital at Chemical Bank Of New York, Wheat First Securities, Crestar Capital and Hillcrest Group. He is a graduate of Princeton University and the Darden School of Business at the University of Virginia.
Dane Carl Andreeff is the current President, Chief Executive Officer and Director at Helius Medical Technologies, Inc., an advanced medical device company focused on improving neurological health and wellness. He is also the founder of Maple Leaf Partners, LLC and Andreeff Equity Advisors, LLC.
In addition to his role as Director at MSI, Andreeff is Director at HDL Therapeutics, a highly innovative medical company that has developed the first therapy of its kind to rapidly reverse coronary atherosclerosis in patients with Homozygous Familial Hypercholesterolemia (HoFH). He is also on the board at TraceSecurity, LLC, a security company helping to protect and eliminate risk for companies ranging local and community financial institutions to global enterprises.
William Burke is currently President at Austin Highlands Advisors, L.L.C., and in addition to MSI, is Director of Adtalem Global Education and Tactile Systems Technology, Inc. Burke’s strong experience in strategy development, mergers and acquisitions, and debt and equity financing. Previously, Burke served as Executive Vice President and Chief Financial Officer at IDEV Technologies, Inc., a subsidiary of Abbott, Inc. providing next-generation medical devices for use in interventional radiology, vascular surgery and cardiology.
Burke also notably served as Executive Vice President and Chief Financial Officer at ReAble Therapeutics, Inc. for over three years, a diversified orthopedic device company, where he increased annual revenues from $100 million to $450 million through means of both acquisitions and organic growth.
Randy Hill currently serves as a key business advisor to United Imaging in North America and specializes in consulting innovative companies across the healthcare imaging sector. Hill brings extensive experience in the medical imaging industry and a background in sales in marketing to help position MSI at the forefront of imaging innovation.
Hill has also served as Chief Executive Officer at Siemens Medical, and previously as Chief Operations Officer and VP of Service at Siemens for more than eight years. Prior to that, Hill served six years as Chief Executive Officer and Director at VasoMedical subsidiary, Vaso Diagnostics, a medical technology company ranging a diverse product and service selection, including several diagnostic imaging solutions as well as non-invasive monitoring and therapeutic devices.
Todd Robinson currently serves as CEO/Principal at Southwood Group, L.L.C., with approximately $45 million in revenue and 200 employees. Robinson also serves as Managing Partner for Hanover Ventures, L.L.C., a venture partnership currently holding three primary investments, including Myocardial Solutions, Inc., VazTec, L.L.C. American Nano, L.L.C. Robinson brings in a diverse background and significant operating experience as both a manager and director.
United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, has partnered with Myocardial Solutions Inc. to bring rapid cardiac MR imaging to unmet cancer care and cardiology markets, helping enable physicians to protect and manage patient heart health during and after cancer treatment.
United Imaging is the preferred provider for MyoStrain®, and the two companies have joined together to deliver this dedicated solution to cancer centers and hospitals. The FDA’s 510(k) pre-market clearance of MyoStrain for United Imaging MRI machines marks the availability of this novel, proprietary technology in the U.S. market.
Learn more about the uMR® 570 MyoStrain® Edition
“With this joint solution from Myocardial Solutions and United Imaging, oncologists and cardiologists will be able to monitor patient heart health before, during, and after cancer treatment. Together, United Imaging and Myocardial Solutions will deliver the diagnostic testing using MyoStrain software on a dedicated MR scanner for both cancer centers and cardiologists. The fast, MR based technique is highly automated to deliver reproducible results.”
Myocardial Solutions’ (MSI) mission is to give cardiac and oncology patients control over their heart health. By quantifying subtle changes in myocardial heart function, MSI's proprietary MyoStrain® technology provides a standardized, proactive approach to help physicians effectively detect, monitor, and manage the early progression of myocardial dysfunction.
With 70,000+ patient data points from over 70 medical centers in the United States and EU, MyoStrain has been rigorously validated in over 400+ publications, including 50+ in JACC and Circulation. The MyoStrain heart function test is a rapid, non-invasive MRI scan performed in under 10 and has been optimized for clinical use due to its speed, ease of use, and quantitative accuracy.
We are working with hospitals and cancer centers in the United States and Europe to help transform quality of care for their patients. Together, we are pursuing a higher standard of care, focusing preventative care and personalized medicine to ultimately improve patient longevity and quality of life in cardiology and oncology.
